Staphylococcus Aureus Bacteremia Clinical Trial
Official title:
Early Infectious Disease Consultation for Better Outcomes From Staphylococcus Aureus Bacteremia
The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB). This study will also determine if such consultations could reduce the duration of hospitalisation, recurrence and financial costs in patients with this infection.
Bacteremia is a serious manifestation of Staphylococcus aureus infection with an
attributable mortality as high as 25% in MRSA bacteremia. More than a third of patients end
up with complications such as endocarditis, osteomyelitis or pneumonia.
Overall the outcome of patients with respect to mortality or recurrence is better in
patients who have an eradicable focus and have received an appropriate antibiotic dose and
duration. Also complicated bacteremia is more common in patients with
- persistent bacteremia or fever
- prosthetic device
- new murmur
- skin findings of a systemic infection
Based on this evidence, an ID consultation could improve the outcomes of patients with SAB
by
- Advising adequate antibiotic dosage and duration
- Sourcing out and counselling eradication of any focus of infection
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05862025 -
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
|
N/A | |
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Recruiting |
NCT06168474 -
Evaluating Simplified Layered Consent for Clinical Trials
|
N/A | |
Completed |
NCT03163446 -
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
|
Phase 2 | |
Not yet recruiting |
NCT06336824 -
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
|
Phase 3 | |
Completed |
NCT02357966 -
A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
|
Phase 1/Phase 2 | |
Recruiting |
NCT04886284 -
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
|
Phase 2 | |
Terminated |
NCT03089697 -
Phase IIa Clinical Study of N-Rephasin® SAL200
|
Phase 2 | |
Recruiting |
NCT03514446 -
Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia
|
Phase 4 | |
Withdrawn |
NCT03761953 -
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
|
Phase 4 | |
Recruiting |
NCT06249451 -
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
|
N/A | |
Recruiting |
NCT02098850 -
Staphylococcus Aureus Bacteraemia in Adults
|
N/A | |
Completed |
NCT01701219 -
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
|
Phase 4 | |
Recruiting |
NCT05137119 -
Staphylococcus Aureus Network Adaptive Platform Trial
|
Phase 4 | |
Completed |
NCT03908086 -
Bloodstream Infections in Patients With Rheumatoid Arthritis
|
||
Terminated |
NCT04160468 -
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
|
Phase 3 | |
Completed |
NCT03138733 -
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
|
Phase 3 | |
Completed |
NCT02476487 -
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
|
N/A | |
Recruiting |
NCT05184764 -
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
|
Phase 1/Phase 2 | |
Completed |
NCT01971762 -
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
|
N/A |